Introduction
Transitions in the mammalian cell cycle are governed by cyclin-dependent kinases (Cdks) whose activities are determined by cyclin binding, small Cdk inhibitor proteins and both positive and negative regulatory phosphorylations (Nilsson, 2000) . The Cdc25 phosphatases are members of the tyrosine phosphatase family and catalyze dephosphorylation and activation of cyclin/ Cdk complexes through removal of inhibitory phosphorylations. In human cells, three Cdc25 homologs called Cdc25A, Cdc25B and Cdc25C have been identi®ed (Sadhu et al., 1990; Galaktionov and Beach, 1991) . Cdc25C dephosphorylates cyclin B/Cdk1, thereby activating its kinase activity. Cdc25C in turn becomes phosphorylated by cyclin B/Cdk1 thus creating a positive feedback loop leading to entry into mitosis (Homann et al., 1993) . Recent work indicates that Cdc25B seems to play the role of a`starter phosphatase' by activating cyclin B/Cdk1 in order to initiate the positive feedback mechanism (Lammer et al., 1998; Karlsson et al., 1999) . Cdc25 phosphatases are main players of the G2 arrest caused by DNA damage or in the presence of unreplicated DNA (Sanchez et al., 1997; Peng et al., 1997) . Cdc25A and B are putative human oncogenes (Galaktionov et al., 1995 (Galaktionov et al., , 1997 . The Cdc25A phosphatase plays a crucial role at the G1/S phase transition as shown by microinjection experiments using Cdc25A speci®c antibodies (Homann et al., 1994) and by conditional overexpression of Cdc25A (Blomberg and Homann, 1999) . Cdc25A functions by activating cyclin E-and cyclin A-dependent kinases (Blomberg and Homann, 1999) .
Studies on human papillomavirus type 16 have demonstrated that the product of the early gene E7, plays a key role in the immortalization and malignant transformation of the host cell. The E7 protein is the major oncogenic protein produced by cervical cancerassociated HPV-16 (reviewed in zur Hausen, 1999) . The majority of the transforming potential of E7 protein has been ascribed to its ability to bind to, and down-regulate the retinoblastoma (RB) gene product (Boyer et al., 1996; Lee et al., 1998) . Loss of RB function causes the release and activation of multiple E2F transcription factor family members, leading to cell cycle progression through the G1/S phase transition. (Funk et al., 1997) . Ectopic expression of E2F1, E2F2, E2F3 and to a lesser extent E2F4 is sucient to induce S-phase in immortalized quiescent rat ®broblasts (Lukas et al., 1996; DeGregori et al., 1997) . Genes that are responsive to E2F include well-studied cell cycle regulators including cyclin E, cyclin A, Cdk1 and Cdk2 (Dalton, 1992; Ohtani et al., 1995; Schulze et al., 1995; Botz et al., 1996; Arata et al., 2000) . Recently it has been shown that TGFbmediated down-regulation of Cdc25A in keratinocytes is mediated by an E2F site within the Cdc25A promoter (Iavarone and Massague, 1999) . Cdc25A is an essential target for E2F1, since its activity is required for ecient induction of S phase by E2F1 and RB family members (Vigo et al., 1999; Chen and Prywes, 1999) .
In this study we show that the human Cdc25A promoter can be transactivated by the E7 oncogene of human papillomavirus type 16. This transactivation is mediated through two functional E2F binding sites within the promoter. Furthermore Cdc25A levels are highly increased in E7-expressing cell lines. Inducible expression of E7 leads to an immediate increase in Cdc25A protein levels. These results suggest that the transcriptional regulation of the Cdc25A gene contributes to the control of cell cycle progression in virally transformed ®broblasts.
Results
Characterization of the functional E2F sites in the human Cdc25A promoter
The region from 7457 to +121 of the human Cdc25A promoter contains potential binding sites for known transcription factors, among them an E2F binding site denoted E2F-A, which is located 60 bp upstream of the transcriptional start site (Iavarone and Massague, 1999) . The same authors also identi®ed a second E2F site (E2F-B) spanning the transcriptional start site. We have isolated the human Cdc25A promoter and identi®ed an additional putative E2F binding site in the promoter, E2F-C, which is located at 160 bp upstream of the transcriptional start site in the promoter (Figure 1, upper panel) . This site diers from the prototype E2F site in nucleotide sequence and protein binding. An E2F-binding site with a similar sequence motif was previously found in the cyclin A promoter (Schulze et al., 1995; Figure 1, middle panel) . To determine which of the E2F sites is functional we transfected wild-type or mutant Cdc25A promoter constructs (nt 7457/+121) driving a luciferase reporter gene into NIH3T3 cells that were serum-starved and then released from the block. Samples were taken at the indicated time points. In Figure 2a the percentage of cells in G1, S and G2 or M phase are shown. While the Cdc25A promoter is repressed during G0 (Iavarone and Massague, 1999;  Figure 2b ), the Cdc25A wild-type promoter construct was induced threefold at 16 h after serum-induction when the cells were in mid S-phase. These results are in agreement with previously published results (Chen and Prywes, 1999) . Mutation of the E2F-A binding site (MUT 1) (Figure 1 , lower panel) leads to a similar fold of induction as found for the wild-type promoter activity in such an experiment. This would suggest that another site of induction is present in the Cdc25A promoter. To test this we mutated the E2F-C site, MUT 2 (Figure 1, lower panel) , and determined the promoter activity. Mutation of both E2F binding sites (MUT3) (Figure 1 , lower panel) only showed a slight increase in promoter activity (Figure 2b ) which could be due to the third E2F site that is present in the promoter, E2F-B (Vigo et al., 1999) . Taken together these results show that the E2F-A and E2F-C sites are both functional and required for E2F-induced S-phase entry.
Transactivation of the Cdc25A gene by the E7 oncoprotein of human papillomavirus type 16
Since we identi®ed functional E2F binding sites in the Cdc25A promoter we asked if expression of HPV-16 E7 would lead to an activation of Cdc25A transcription in NIH3T3 cells. An expression vector for HPV-16 E7 was co-transfected with the Cdc25A promoter construct into NIH3T3 cells and the relative luciferase activity was determined. As shown in Figure 3a a threefold increase of Cdc25A promoter activity was observed when HPV-16 E7 was co-transfected in comparison to the co-transfection of an empty vector. In order to demonstrate that only a high-risk papillomavirus oncogene as HPV-16 E7 is able to transactivate the Cdc25A promoter we also cotransfected a protein from the low-risk papilloma virus, HPV-11 E7. As expected, HPV-11 E7 is not able to transactivate the Cdc25A promoter. The transactivation experiments shown in Figure 3a were repeated with vectors containing HPV-16 E7 or HPV-11 E7 that were fused to a NH2-terminal epitope tag from in¯uenza hemagglutinin (HA). Similar results to the HPV E7 proteins without a HA-tag were obtained (data not shown). The expression levels of both HPV-11 E7 and HPV-16 E7 proteins after transient transfection into NIH3T3 cells was similar as shown by immunoblotting with the 3F10 monoclonal antibody that detects speci®cally the HA-tagged proteins ( Figure 3b ).
Having identi®ed two functional E2F binding sites in the Cdc25A promoter we compared the transactivation of HPV-16 E7 on the mutant Cdc25A promoter constructs. Figure 3c shows that the Cdc25A promoter activity is about ®ve times increased after transactivation by E7 when either the E2F-A site (MUT 1) or the E2F-C site (MUT 2) are mutated. Only a low transactivation rate was observed when both E2F sites were mutated. These results indicate that both E2F sites can be used for E7-mediated transactivation of the Cdc25A gene. To further evaluate the role of the HPV-16 E7 oncoprotein in the modulation of Cdc25A gene expression we prepared total cell extracts from NIH3T3-derived E7-expressing (E7/2) cells (Lam et al., 1994) and control NIH3T3 cells. As expected HPV-16 E7 is highly expressed in E7/2 cells and not present in control cells (Figure 4a) . A higher expression rate was also detected for the G1 cyclins E and A in E7/2 cells. Similarly Cdc25A protein is highly expressed in the E7-overexpressing cell line which suggests that its expression may be modulated by the viral oncoprotein.
To investigate the mode of action of HPV-16 E7 in cell transformation Crook et al. (1989) developed a system of inducible expression of the E7 oncoprotein in eukaryotic cells based on the ability of the mouse mammary tumor virus long terminal repeat (MMTV-LTR) to respond to glucocorticoid hormones. These cells, called 14/2 cells are derived from baby rat kidney cells and are arrested in G1 in the absence of hormone, and progress through S-phase with high synchrony upon addition of dexamethasone which induces the expression of E7. To investigate the eect of E7-dependent cell transformation on Cdc25A gene activation in 14/2 cells, expression of E7 was induced through addition of 1 mM of dexamethasone to the medium. Progression of cells into S-phase was monitored by FACScan analysis. Cells started to synthesize DNA at 10 h after addition of hormone (Table 1) . RNA was prepared at regular time intervals after addition of dexamethasone. Expression of E7 and Cdc25A genes were monitored by Northern blotting (Figure 4b ). E7 mRNA was absent in control preparations and was ®rst detected at 2 h after hormone addition at the same time as Cdc25A mRNA appeared. To examine whether there was a corresponding change in protein levels, cell extracts were prepared at regular time intervals after the addition of hormone. Protein expression of E7, cyclins A and E and Cdc25A was monitored by immunoblotting ( Figure 4c ). The expression of E7 was detected at 3 h after the addition of dexamethasone while Cdc25A protein expression was ®rst observed after 3 ± 4 h. Cyclin E protein expression is present during the whole time course but the levels increased threefold at 3 h after hormone addition. Thus cyclin E expression is increased at the same time as Cdc25A expression ®rst appears, while cyclin A expression increases much later, at 10 h after addition of dexamethasone (Figure 4c) . From the timing of expression these results indicate that Cdc25A could act as a direct target for E7-dependent induction of S-phase entry. Regulation of the Cdc25A gene by the transcription factors E2F1 and E2F4
The motifs TTTGGCGC (E2F-A) and TCCCGC (E2F-C) are present at positions 762/755 and 7153/7158, respectively, of the human Cdc25A promoter (Figure 1) . To analyse the binding of cellular proteins to these motifs, we performed bandshift experiments using the oligonucleotide containing either the E2F-A or the E2F-C motif with nuclear extracts from NIH3T3 cells. Figure 5a , upper panel shows the results using the E2F-A motif. It reveals a strong band that we identi®ed as unbound or`free E2F' since preincubation of the nuclear extracts from NIH3T3 cells with GST-RB leads to a retardation of the band. Free E2F, the smallest E2F complexes, are heterodimers containing a subunit encoded by the E2F gene family and a subunit encoded by the DP family of genes. In addition, experiments using speci®c antibodies against human E2F1 and E2F4 lead to a supershift of the free E2F band. No supershifts were observed when antibodies against E2F2 or E2F3 were used. An additional cellular complex that binds to the E2F-A site, was identi®ed in the Cdc25A promoter (Figure 5a upper panel, complex A). We then performed bandshift experiments with the oligonucleotide containing the E2F-C motif (Figure 5a , lower panel). In those experiments we also detected a`free E2F' which was shifted upon incubation with GST-Rb. Antibodies against the E2F1 but not E2F2, E2F3 or E2F4 supershifted the free E2F band. We found two cellular complexes that bind to the E2F-C site ( Figure  5a lower panel, complexes B and C). In addition we analysed the formation of these cellular complexes binding to either the E2F-A or E2F-C site in serumstarved and serum-stimulated cells. Figure 5b shows that complex A is absent in serum-starved NIH3T3 cells but its formation is markedly increased at 24 h after serum-stimulation. Similarly, the complexes B and C that bind to the E2F-C site are absent in serumstarved cells but appear at 24 h after serum-stimulation.
To test which RB family member was present in complex A we used antisera to p107 and p130 in supershift assays. We found that both p107 (A') and p130 (A'') were present in the complexes. In agreement with previously published data (Chen and Prywes, 1999), we also show by supershift experiments that RB itself is not present in the complex. If HPV-16 E7 directly interacts with the E2F-A site of the Cdc25A promoter, incubation of E7 with the oligonucleotide containing the motif should result in an increase of free' E2F band. To demonstrate this we incubated HPV-16 E7 that was expressed as fusion protein to glutathione-S-transferase (GST) with nuclear extracts from NIH3T3 cells. Figure 5d , right panel shows that the amount of free E2F is markedly increased due to the presence of E7 while no increase was observed when GST alone was used or by incubation with an E7 mutant, GST-E7(Gly24), that is de®cient of binding to the pocket domain of pRB.
To demonstrate that E7 is able to sequester p107 or p130 from complex A, we incubated nuclear extracts from NIH3T3 or E7/2 cells with an oligonucleotide containing the E2F-A motif. As shown in Figure 5d , right panel, complex A is absent in extracts containing functional E7 protein.
Discussion
To further analyse how papillomavirus oncoproteins disrupt cell cycle control we investigated the 5' regulatory region of the human Cdc25A gene and analysed its activation by the E7 oncogene of human papillomavirus type 16. The Cdc25A promoter contains two functional E2F sites, denoted E2F-A and E2F-C. Mutation of both sites in the promoter abrogated its G1/S-speci®c induction and released its repression during G1. Transactivation of the Cdc25A promoter by E7 can be mediated through both E2F binding sites. The protein levels of Cdc25A are markedly increased in NIH3T3 cells that are stably transfected with E7. Moreover, dexamethasone-dependent activation of HPV-16 E7 gene expression in 14/2 cells leads to an immediate activation of Cdc25A gene expression. Taken together, these results suggest that Cdc25A is a crucial target of HPV-16 E7 in virusmediated transactivation of cells.
A large number of promoters contain potential E2F binding sites and, in a few cases, mutation of the binding sites has con®rmed that E2F is critical for cellcycle regulated transcription. We have shown that two of the three putative E2F binding sites in the Cdc25A promoter, i.e. E2F-A and E2F-C, are required for E2F-mediated S-phase entry (Figure 2 ). Mutation of E2F-A and E2F-C sites prevents an increase of Cdc25A promoter activity when cells enter S-phase. These results indicate that the third E2F-site in the Cdc25A promoter, E2F-B, has only a small eect on S-phase. Our results are in good agreement with the results published by Iavarone and Massague (1999) who showed that the E2F-B site is not a functional E2F site in the Cdc25A promoter. Interestingly, the E2F-C site of the Cdc25A promoter varies from the consensus E2F site motif in nucleotide composition. A similar E2F site motif represents also the functional E2F site in the Cyclin A promoter. In the cyclin A promoter cell cycle regulation is determined by this single promoter element (Schulze et al., 1995) . Our results also indicate that the cellular complexes that bind to either functional E2F binding site of the Cdc25A promoter are dierent (Figure 5a ). Cell lines that allow an inducible expression of E2F1 fused to the estrogen receptor reveal that Cdc25A is an E2F1 target gene and that Cdc25A is not transactivated by either E2F2 and E2F3 (Vigo et al., 1999) . In our hands addition of antibodies to both E2F1 and E2F4 lead both to a supershift of the complexes that are bound to this site suggesting that this particular E2F site is regulated by both E2F proteins. The other functional E2F binding site, E2F-C, seems to be regulated only by E2F1. Taken together, the E2F-A Nuclear extracts from NIH3T3 cells were pre-incubated with GST alone, GST/HPV-16 E7 and GST/HPV-16 E7 (Gly24). A 32 Plabelled oligonucleotide containing the E2F-A site was then incubated with these nuclear extracts. Right panel, analysis of the complexes binding to the E2F-A site in cell lines with or without expression of E7. A 32 P-labelled oligonucleotide containing the E2F-A site was incubated with nuclear extracts of either NIH3T3 or E7/2 cells site in the Cdc25A promoter seems to be regulated dierently from the second functional E2F site in the promoter (E2F-C). In the future, it will be interesting to perform a detailed analysis of the molecular components that are bound to the E2F-C site.
Overexpression of Cdc25A in rat-1 cells leads to an immediate activation of cyclin E and Adependent kinase activities (Blomberg and Homann, 1999) suggesting that these Cdk/cyclin complexes act as in vivo substrates of Cdc25A. Inducible overexpression of HPV-16 E7 in the BRK cell line 14/2 leads to a rapid increase in Cdc25A protein levels at the same time when cyclin E protein levels augment but way before cyclin A protein levels increase. Overexpression of the Cdc25A gene induced by E7 would then lead to an increase in Cdc25A phosphatase activity which in turn activates cyclin E and cyclin A dependent kinases leading to entry into S-phase. This study provides new insights into the mechanisms of how viral oncogenes may overcome checkpoint control mechanisms during G1 to induce entry into S-phase.
Materials and methods
Cell culture and cell cycle analysis NIH3T3 cells were obtained from the American Type Culture Collection. The E7/2 clone, expressing wild type HPV-16 E7 was obtained from K Vousden (MD, USA). Both cell types were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% calf serum, 2 mM glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml).
The BRK cell line 14/2 was a kind gift from L Banks (Trieste, Italy). The cell line was grown in DMEM, supplemented as above, containing 1 mM dexamethasone. 14/2 cells were synchronized by hormone withdrawal for 48 h; cell proliferation was induced by readdition of 1 mM dexamethasone.
Cell cycle progression was monitored by¯uorescence-activated cell sorter (FACS) analysis, using a Becton Dickinson FACScan system, the Cell Quest and ModFit 2.0 software. The blocked or induced cells were trypsinized, washed and resuspended in 0.2 ml phosphate-buered saline (PBS). Fixation occurred by addition of 0.8 ml of ice-cold methanol and incubation at 48C for at least 20 min. After centrifugation the pellet was resuspended in 1 ml of PI mix (50 mg of propidium iodide per ml, 10 mM Tris-HCl, pH 7.5; 5 mM MgCl 2 ; 10 mg of RNase A per ml) per 10 6 cells.
Transient transfections and luciferase assay
NIH3T3 cells were plated on six well plates at a density of 1610 5 cells and transfected using the Eectene Kit from Qiagen (Hilden, Germany). Two mg of DNA were diluted in EC buer to a ®nal volume of 100 ml. To condense the DNA Enhancer (8 ml/mg DNA) was added and mixed. Then the transfection reagent Eectene (2 ml/mg DNA) was added and incubated for 10 min. Six hundred ml of media was added to the transfection mix and distributed to each well containing 1.6 ml media. After 15 ± 20 h the cells were washed twice with serum free media and fresh media containing 10% calf serum, or for transactivation assays 0.5% serum was added for another 24 h. Cells were lysed in Triton buer (25 mM Tris pH 7.5, 15 mM MgSO 4 , 4 mM EGTA, 1 mM DTT, 1% Triton X-100) and luciferase activity was measured in triplicate samples.
Variations in transfection eciency were accounted for by normalizing to a cotransfected cytomegalovirus promoterdriven b-galactosidase control plasmid (pCMV-bgal) (Rentrop, DKFZ, Heidelberg).
Reporter plasmids and expression vectors
To obtain the Cdc25A wildtype promoter construct, a human pCYPAC library (Ioannou et al., 1994) was screened with a 32 P-labelled 386 bp probe (1620 ± 2006 bp of the Cdc25A open reading frame). The DNA of a positive clone was used as a template in a PCR using the primers PROM1 (5'-CTCGAATCCGGCCAGACCTCC-3') and PROM2 (5'-AA-GCTTCGAGGCAACGGCCCAG-3'). After sequencing, the PCR product was cloned into the pBL luciferase reporter vector (Hoppe-Seyler and Butz, 1992) . The promoter constructs MUT1, MUT2 and MUT3 were also generated by PCR using the additional primers E2FM1 (5'-TTCCTAGTTGGAAGGTAACGGAATCCA-3'), E2FM2 (reverse to E2F1), E2FM3 (5'-AAAGCGGCTCGATATCT-CTGCCAGGT-3') and E2FM4 (reverse to E2F3) to delete E2FA, E2FC or both sites.
The expression vector pX/HPV-16 E7 was a gift of P Jansen-DuÈ rr (Innsbruck, Austria). In order to detect its proper protein expression, a hemagglutinin (HA)-tag was cloned in front of the HPV-16 E7 open reading frame.
The expression vectors pX/HPV-11 E7 and pX/HPV-11 HA-E7 were constructed by PCR using HPV-11 E7 containing DNA as a template. The resulting PCR products were cloned into the pX vector (G Superti-Furga, EMBL Heidelberg, Germany).
Electrophoretic mobility shift assay
The bandshift shift assays were performed using NIH3T3 or E7/2 nuclear extracts. Pellets of exponentially grown cells were resuspended in ice cold buer A (10 mM HEPES, pH 7.9; 10 mM KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 mM PMSF) and incubated 15 min on ice. To lyse the cells, 10% NP40 was added carefully, immediately mixed and left on ice for another 5 min. The lysate was then centrifuged at 48C at 13 000 rpm for 2 min. The remaining pellet containing the nuclei was resuspended in buer C (20 mM HEPES pH 7.9; 0.4 M NaCl; 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF), incubated on ice for 20 min and centrifuged at 48C at 13 000 rpm. The supernatant representing the nuclear extract was then tested by Western blot for purity.
Double stranded oligonucleotides E2F1B/2B (5'-GAT-CACCTGGCAGAGTCCCGCGAGCCGCT-3') or E2F3B/ 4B (5'-GATCTGGATTCCGTTTGGCCCAACTAGGAA-3') were 32 P-end-labelled with Klenow enzyme and diluted in 50% glycerol to a concentration of 20 000 c.p.m./ml. Two ml of the labelled probe was mixed with 10 mg of nuclear extract, 100 or 200 ng of sonicated salmon sperm DNA and 1 ml of 20 mM MgCl 2 to a ®nal volume of 10 ml and incubated at room temperature for 10 min. The reaction mix was separated by electrophoresis in a 4.5% native polyacrylamide gel at 48C. After ®xation in a 10% methanol/ 20% ethanol solution for 15 min and drying, the gel was exposed to ®lm.
For supershifts, the extracts were preincubated with speci®c antibodies prior to the addition of labelled oligonucleotides for 45 min at 48C. Monoclonal antibodies to p130(C20x), and E2F1(C-20x) E2F2(C-20x), E2F3(N-20x) were obtained from Santa Cruz Biotechnology, hybridoma supernatants E2F4 (WUF11) and p107 (SD15) were gifts from N Dyson (Charlestown, MA, USA).
For competition assays, 100 ng of unlabelled wild-type or mutated oligonucleotides (E2FM1/E2FM2) were preincubated in the same way as the antibodies.
One hundred ng of recombinant proteins GST, GST-RB (379 ± 928, containing the pocket domain of pRB), GST-HPV16 E7 or GST-Gly24 (an HPV-16 E7 mutant, which is unable to bind the pRB pocket domain) were preincubated in the same way as the antibodies.
Northern blotting
Total cellular RNA was prepared by the guanidinum thiocyanate-acid phenol method. Total RNA samples (10 mg) were separated on formaldehyde agarose gels and transferred to Hybond N + membranes (Amersham Pharmacia) by capillary transfer.
A 340 bp EcoRI ± HindIII E7 cDNA fragment was used for detection of HPV-16 E7 expression. Expression of Cdc25A was monitored with a human probe, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression was analysed by using a rat cDNA probe .
Western blotting
Whole cell extracts were prepared by lysing cell pellets in RIPA buer (10 mM Tris-HCl pH 8.0; 150 mM NaCl; 1 mM EDTA; 1% NP-40; 0.1% SDS; 50 mM NaF, 0.1 mM Na 3 VO 4 , 1 mM DTT, 0.1 mM PMSF). After clearing o the lysate by centrifugation, the protein content in the lysate was determined by the Bradford method. A 40 mg quantity of protein extract were separated by SDS ± PAGE, blotted to nitrocellulose and probed with monoclonal antibodies to Cdc25A (F6, Santa Cruz Biotechnology), HPV-16 E7 (8C9, Zymed), cyclin E (M-20, Santa Cruz Biotechnology), HA-tag (3F10, Roche) and polyclonal antisera to cyclin A (Pagano et al., 1992) . Equal loading of the samples was determined by staining with Ponceau S and antibodies against Cdk2. Samples were detected with a peroxidase-linked chemiluminescence detection system (Santa Cruz Biotechnology).
